1	NEW	new	JJ	p2=NNP	2	nn	_
2	YORK	york	NNP	p2=NN	4	nn	_
3	(	(	-LRB-	_	4	punct	_
4	AP	ap	NNP	_	0	root	_
5	)	)	-RRB-	_	4	punct	_
6	-	-	:	p2=.	10	punct	_
7	U.S.	u.s.	NNP	_	9	nn	_
8	drugmaker	drugmaker	NNP	p2=NN	9	nn	_
9	Pfizer	pfizer	NNP	_	10	nsubj	10:A0
10	said	say	VBD	pb=say.01	0	root	_
11	Sunday	sunday	NNP	_	10	npadvmod	10:AM-TMP
12	that	that	IN	p2=WRB	15	complm	_
13	it	it	PRP	_	15	nsubj	15:A0=PAG;27:A0=PAG
14	has	have	VBZ	_	15	aux	_
15	raised	raise	VBN	pb=raise.01	10	ccomp	10:A1=PPT
16	its	its	PRP$	_	17	poss	_
17	offer	offer	NN	_	15	dobj	15:A1=PPT
18	for	for	IN	_	17	prep	_
19	British	british	JJ	_	21	amod	_
20	rival	rival	JJ	p2=NN	21	amod	_
21	AstraZeneca	astrazeneca	NNP	_	18	pobj	_
22	for	for	IN	_	15	prep	15:AM-TMP
23	a	a	DT	_	25	det	_
24	third	#ord#	JJ	_	25	amod	_
25	time	time	NN	_	22	pobj	_
26	,	,	,	_	15	punct	_
27	hiking	hike	VBG	pb=hike.01	15	advcl	15:AM-ADV
28	its	its	PRP$	_	34	poss	_
29	stock	stock	NN	_	34	nn	_
30	-	-	HYPH	_	29	hyph	_
31	and	and	CC	_	29	cc	_
32	-	-	HYPH	_	33	hyph	_
33	cash	cash	NN	_	29	conj	_
34	offer	offer	NN	_	27	dobj	27:A1=LOC
35	by	by	IN	_	27	prep	27:AM-MNR
36	15	0	CD	_	37	num	_
37	percent	percent	NN	_	35	pobj	_
38	to	to	IN	p2=TO	27	prep	_
39	worth	worth	JJ	_	38	pobj	_
40	$	$	$	_	42	quantmod	_
41	118.8	0	CD	_	42	number	_
42	billion	#crd#	CD	_	39	npadvmod	_
43	,	,	,	_	42	punct	_
44	or	or	CC	_	42	cc	_
45	70.73	0	CD	_	46	number	_
46	billion	#crd#	CD	_	47	num	_
47	pounds	pound	NNS	_	42	conj	_
48	.	.	.	_	10	punct	_

1	If	if	IN	_	5	mark	_
2	the	the	DT	_	3	det	_
3	deal	deal	NN	_	5	nsubjpass	5:A1=PPT
4	is	be	VBZ	_	5	auxpass	_
5	accepted	accept	VBN	pb=accept.01	27	advcl	27:AM-ADV
6	-	-	:	p2=,	5	punct	_
7	and	and	CC	_	5	cc	_
8	it	it	PRP	_	9	nsubj	9:A1=PPT
9	's	be	VBZ	pb=be.01	5	conj	_
10	no	no	DT	p2=UH	12	det	_
11	sure	sure	JJ	_	12	amod	_
12	thing	thing	NN	_	9	attr	9:A2=PRD
13	,	,	,	_	27	punct	_
14	given	give	VBN	_	27	prep	27:AM-ADV
15	opposition	opposition	NN	_	14	pobj	_
16	to	to	IN	_	15	prep	_
17	date	date	NN	_	16	pobj	_
18	from	from	IN	_	15	prep	_
19	AstraZeneca	astrazeneca	NNP	_	18	pobj	_
20	and	and	CC	_	15	cc	_
21	the	the	DT	_	23	det	_
22	British	british	JJ	_	23	amod	_
23	government	government	NN	_	15	conj	_
24	-	-	:	_	27	punct	_
25	it	it	PRP	_	27	nsubj	27:A1=PPT
26	would	would	MD	_	27	aux	27:AM-MOD
27	be	be	VB	pb=be.01	0	root	_
28	the	the	DT	_	30	det	_
29	richest	rich	JJS	_	30	amod	_
30	acquisition	acquisition	NN	_	27	attr	27:A2=PRD
31	ever	ever	RB	_	30	advmod	_
32	among	among	IN	_	30	prep	_
33	drugmakers	drugmaker	NNS	_	32	pobj	_
34	and	and	CC	_	30	cc	_
35	the	the	DT	_	39	det	_
36	third	#ord#	RB	_	38	hmod	_
37	-	-	HYPH	_	38	hyph	_
38	biggest	big	JJS	_	39	amod	_
39	deal	deal	NN	_	30	conj	_
40	in	in	IN	_	39	prep	_
41	any	any	DT	_	42	det	_
42	industry	industry	NN	_	40	pobj	_
43	,	,	,	_	27	punct	_
44	according	accord	VBG	_	27	prep	_
45	to	to	IN	_	44	prep	_
46	figures	figure	NNS	_	45	pobj	_
47	from	from	IN	_	46	prep	_
48	research	research	NN	_	49	nn	_
49	firm	firm	NN	p2=JJ	50	nn	_
50	Dealogic	dealogic	NNP	_	47	pobj	_
51	.	.	.	_	9	punct	_

1	It	it	PRP	_	3	nsubj	3:A1=PPT
2	would	would	MD	_	3	aux	3:AM-MOD
3	be	be	VB	pb=be.01	0	root	_
4	Pfizer	pfizer	NNP	_	7	poss	_
5	's	's	POS	_	4	possessive	_
6	fourth	#ord#	JJ	_	7	amod	_
7	deal	deal	NN	_	3	attr	3:A2=PRD
8	worth	worth	JJ	p2=NN	7	amod	_
9	$	$	$	_	11	quantmod	_
10	60	0	CD	_	11	number	_
11	billion	#crd#	CD	_	8	npadvmod	_
12	or	or	CC	_	11	cc	_
13	more	more	JJR	_	11	conj	_
14	since	since	IN	_	7	prep	_
15	2000	0	CD	_	14	pobj	_
16	.	.	.	_	3	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nn	_
2	Inc	inc	NNP	_	0	root	_
3	.	.	.	_	2	punct	_

1	,	,	,	_	14	punct	_
2	the	the	DT	_	3	det	_
3	world	world	NN	_	8	poss	_
4	's	's	POS	_	3	possessive	_
5	second	#ord#	RB	_	7	hmod	_
6	-	-	HYPH	_	7	hyph	_
7	biggest	big	JJS	p2=RBS	8	amod	_
8	drugmaker	drugmaker	NN	_	14	nsubj	14:A0=PAG;22:A0
9	by	by	IN	_	8	prep	_
10	revenue	revenue	NN	_	9	pobj	_
11	,	,	,	_	14	punct	_
12	has	have	VBZ	_	14	aux	_
13	been	be	VBN	_	14	aux	_
14	courting	court	VBG	pb=court.01	0	root	_
15	No.	no.	NN	p2=NNP	18	nn	_
16	8	0	CD	_	15	num	_
17	AstraZeneca	astrazeneca	NNP	_	18	nn	_
18	PLC	plc	NNP	_	14	dobj	14:A1=COM
19	since	since	IN	_	14	prep	14:AM-TMP
20	January	january	NNP	_	19	pobj	_
21	,	,	,	_	14	punct	_
22	saying	say	VBG	pb=say.01	14	advcl	14:AM-ADV
23	their	their	PRP$	_	24	poss	_
24	businesses	business	NNS	_	25	nsubj	25:A1=PPT;29:A1=PPT
25	are	be	VBP	pb=be.01	22	ccomp	22:A1=PPT
26	complementary	complementary	JJ	_	25	acomp	25:A2=PRD
27	and	and	CC	_	25	cc	_
28	would	would	MD	_	29	aux	29:AM-MOD
29	be	be	VB	pb=be.01	25	conj	_
30	stronger	strong	JJR	p2=RBR	29	acomp	29:A2=PRD
31	together	together	RB	_	29	advmod	29:AM-MNR
32	.	.	.	_	14	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	poss	_
2	's	's	POS	_	1	possessive	_
3	offer	offer	NN	_	4	nsubj	4:A1=PPT
4	comes	come	VBZ	pb=come.01	0	root	_
5	amid	amid	IN	_	4	prep	4:AM-TMP
6	a	a	DT	_	7	det	_
7	surge	surge	NN	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	other	other	JJ	_	10	amod	_
10	deals	deal	NNS	_	8	pobj	_
11	as	as	IN	p2=RB	13	mark	_
12	drugmakers	drugmaker	NNS	_	13	nsubj	13:A0=PPT
13	look	look	VBP	pb=look.01	4	advcl	4:AM-TMP
14	to	to	IN	p2=TO	13	prep	13:A1=GOL
15	either	either	CC	p2=DT	16	preconj	_
16	grow	grow	VB	p2=VBP	14	pobj	_
17	or	or	CC	_	16	cc	_
18	eliminate	eliminate	VB	pb=eliminate.01	16	conj	_
19	noncore	noncore	JJ	p2=NN	20	amod	_
20	assets	asset	NNS	_	18	dobj	18:A1=PPT
21	to	to	TO	_	22	aux	_
22	focus	focus	VB	pb=focus.01	18	advcl	_
23	on	on	IN	_	22	prep	22:A2=PPT
24	their	their	PRP$	_	25	poss	_
25	strengths	strength	NNS	_	23	pobj	_
26	.	.	.	_	4	punct	_

1	Those	those	DT	_	2	det	_
2	deals	deal	NNS	_	3	nsubj	3:A2=GOL
3	include	include	VBP	pb=include.01	0	root	_
4	Switzerland	switzerland	NNP	_	7	poss	_
5	's	's	POS	_	4	possessive	_
6	Novartis	novartis	NNP	_	7	nn	_
7	AG	ag	NNP	_	3	dobj	8:A0=PAG;10:A0=PAG;3:A1=PPT
8	agreeing	agree	VBG	pb=agree.01	7	partmod	_
9	to	to	TO	_	10	aux	_
10	buy	buy	VB	pb=buy.01	8	xcomp	8:A1=PPT
11	GlaxoSmithKline	glaxosmithkline	NNP	_	16	poss	_
12	's	's	POS	_	11	possessive	_
13	cancer	cancer	NN	_	15	hmod	_
14	-	-	HYPH	_	15	hyph	_
15	drug	drug	NN	_	16	nn	_
16	business	business	NN	_	10	dobj	10:A1=PPT
17	for	for	IN	_	10	prep	10:A3=VSP
18	up	up	IN	_	22	quantmod	_
19	to	to	TO	_	22	quantmod	_
20	$	$	$	_	22	quantmod	_
21	16	0	CD	_	22	number	_
22	billion	#crd#	CD	_	17	pobj	_
23	,	,	,	_	7	punct	_
24	to	to	TO	_	25	aux	_
25	sell	sell	VB	pb=sell.01	7	infmod	_
26	most	most	JJS	_	25	dobj	25:A1=PPT
27	of	of	IN	_	26	prep	_
28	its	its	PRP$	_	30	poss	_
29	vaccines	vaccine	NNS	_	30	nn	_
30	business	business	NN	_	27	pobj	_
31	to	to	TO	p2=IN	32	aux	_
32	GSK	gsk	VB	p2=NNP|pb=gsk.01	25	advcl	_
33	for	for	IN	_	32	prep	32:A3
34	$	$	$	_	36	quantmod	_
35	7.1	0	CD	_	36	number	_
36	billion	#crd#	CD	_	33	pobj	_
37	,	,	,	_	7	punct	_
38	plus	plus	CC	_	7	cc	_
39	royalties	royalty	NNS	_	7	conj	_
40	,	,	,	_	3	punct	_
41	and	and	CC	_	3	cc	_
42	to	to	TO	_	43	aux	_
43	sell	sell	VB	pb=sell.01	3	advcl	_
44	its	its	PRP$	_	47	poss	_
45	animal	animal	NN	p2=JJ	47	nn	_
46	health	health	NN	_	47	nn	_
47	division	division	NN	_	43	dobj	43:A1=PPT
48	to	to	IN	_	43	prep	43:A2=GOL
49	Eli	eli	NNP	_	50	nn	_
50	Lilly	lilly	NNP	_	48	pobj	_
51	and	and	CC	_	50	cc	_
52	Co.	co.	NNP	_	50	conj	_
53	of	of	IN	_	50	prep	_
54	Indianapolis	indianapolis	NNP	_	53	pobj	_
55	for	for	IN	_	43	prep	43:A3=VSP
56	about	about	RB	p2=IN	59	advmod	_
57	$	$	$	_	59	quantmod	_
58	5.4	0	CD	_	59	number	_
59	billion	#crd#	CD	_	55	pobj	_
60	.	.	.	_	3	punct	_

1	Meanwhile	meanwhile	RB	_	8	advmod	8:AM-TMP
2	,	,	,	_	8	punct	_
3	Canada	canada	NNP	_	6	poss	_
4	's	's	POS	_	3	possessive	_
5	Valeant	valeant	NNP	_	6	nn	_
6	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	8	nsubj	8:A0
7	has	have	VBZ	_	8	aux	_
8	made	make	VBN	pb=make.LV	0	root	_
9	an	an	DT	_	11	det	_
10	unsolicited	unsolicited	JJ	_	11	amod	_
11	offer	offer	NN	_	8	dobj	8:AM-PRR
12	of	of	IN	_	11	prep	_
13	nearly	nearly	RB	_	16	advmod	_
14	$	$	$	_	16	quantmod	_
15	46	0	CD	_	16	number	_
16	billion	#crd#	CD	_	12	pobj	_
17	for	for	IN	_	11	prep	_
18	Botox	botox	NNP	p2=NN	19	nn	_
19	maker	maker	NN	_	20	nn	_
20	Allergan	allergan	NNP	_	17	pobj	24:A0
21	,	,	,	_	20	punct	_
22	which	which	WDT	_	24	nsubj	24:R-A0
23	has	have	VBZ	_	24	aux	_
24	turned	turn	VBN	pb=turn.05	20	rcmod	_
25	it	it	PRP	_	24	dobj	24:A1=PPT
26	down	down	RP	_	24	prt	24:C-V
27	,	,	,	_	20	punct	_
28	so	so	RB	_	29	advmod	_
29	far	far	RB	_	24	advmod	24:AM-TMP
30	.	.	.	_	8	punct	_

1	This	this	DT	_	2	nsubj	2:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	the	the	DT	_	5	det	_
4	third	#ord#	JJ	_	5	amod	_
5	time	time	NN	_	2	attr	2:A2=PRD;8:AM-TMP
6	Pfizer	pfizer	NNP	_	8	nsubj	8:A0=PAG
7	has	have	VBZ	_	8	aux	_
8	sweetened	sweeten	VBN	pb=sweeten.02	5	rcmod	_
9	its	its	PRP$	_	10	poss	_
10	offer	offer	NN	_	8	dobj	8:A1=PPT
11	,	,	,	_	10	punct	_
12	this	this	DT	_	13	det	_
13	time	time	NN	_	8	npadvmod	8:AM-TMP
14	by	by	IN	_	8	prep	_
15	15	0	CD	_	16	num	_
16	percent	percent	NN	_	14	pobj	_
17	over	over	IN	_	8	prep	8:AM-PRP
18	its	its	PRP$	_	20	poss	_
19	last	last	JJ	_	20	amod	_
20	bid	bid	NN	_	17	pobj	_
21	,	,	,	_	2	punct	_
22	but	but	CC	_	2	cc	_
23	it	it	PRP	_	24	nsubj	24:A1=PPT
24	's	be	VBZ	pb=be.01	2	conj	_
25	the	the	DT	_	28	det	_
26	New	new	NNP	_	27	nn	_
27	York	york	NNP	_	28	nn	_
28	company	company	NN	_	32	poss	_
29	's	's	POS	_	28	possessive	_
30	first	#ord#	JJ	_	32	amod	_
31	formal	formal	JJ	_	32	amod	_
32	proposal	proposal	NN	_	24	attr	24:A2=PRD
33	.	.	.	_	24	punct	_

1	Pfizer	pfizer	NNP	p2=NN	2	nsubj	2:A0
2	says	say	VBZ	pb=say.01	0	root	_
3	it	it	PRP	_	8	nsubjpass	8:A1=PPT
4	"	"	``	_	8	punct	_
5	can	can	MD	_	8	aux	8:AM-MOD
6	not	not	RB	_	8	neg	8:AM-NEG
7	be	be	VB	_	8	auxpass	_
8	increased	increase	VBN	pb=increase.01	2	ccomp	2:A1=PPT
9	"	"	''	p2=``	8	punct	_
10	unless	unless	IN	_	12	mark	_
11	AstraZeneca	astrazeneca	NNP	_	12	nsubj	12:A0=PAG;28:A0=PAG
12	engages	engage	VBZ	pb=engage.01	8	advcl	8:AM-ADV
13	it	it	PRP	_	12	dobj	12:A1=PPT
14	in	in	IN	_	12	prep	12:A2=PPT
15	discussions	discussion	NNS	_	14	pobj	_
16	before	before	IN	_	15	prep	_
17	a	a	DT	_	18	det	_
18	deadline	deadline	NN	_	16	pobj	_
19	of	of	IN	_	18	prep	_
20	5	0	CD	_	21	num	_
21	p.m.	p.m.	NN	p2=RB	22	npadvmod	_
22	British	british	JJ	_	23	amod	_
23	time	time	NN	_	19	pobj	_
24	on	on	IN	_	12	prep	12:AM-TMP
25	May	may	NNP	_	24	pobj	_
26	26	0	CD	_	25	num	_
27	and	and	CC	_	12	cc	_
28	recommends	recommend	VBZ	pb=recommend.01	12	conj	_
29	a	a	DT	_	30	det	_
30	deal	deal	NN	_	28	dobj	28:A1=PPT
31	.	.	.	_	2	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	nsubj	3:A0=PAG;11:A0=PAG
2	also	also	RB	_	3	advmod	3:AM-DIS
3	increased	increase	VBD	pb=increase.01	0	root	_
4	the	the	DT	_	5	det	_
5	ratio	ratio	NN	_	3	dobj	3:A1=PPT
6	of	of	IN	_	5	prep	_
7	cash	cash	NN	_	9	nn	_
8	AstraZeneca	astrazeneca	NNP	p2=NN	9	nn	_
9	shareholders	shareholder	NNS	_	6	pobj	_
10	would	would	MD	_	11	aux	11:AM-MOD
11	receive	receive	VB	pb=receive.01	3	advcl	_
12	,	,	,	_	11	punct	_
13	from	from	IN	_	11	prep	11:A3
14	33	0	CD	_	15	num	_
15	percent	percent	NN	_	13	pobj	_
16	to	to	IN	_	13	prep	_
17	45	0	CD	_	18	num	_
18	percent	percent	NN	_	16	pobj	_
19	.	.	.	_	3	punct	_

1	The	the	DT	_	3	det	_
2	latest	late	JJS	_	3	amod	_
3	offer	offer	NN	p2=VBP	5	nsubj	5:A0=PAG
4	would	would	MD	_	5	aux	5:AM-MOD
5	give	give	VB	pb=give.01	0	root	_
6	them	them	PRP	_	5	iobj	5:A2=GOL
7	the	the	DT	_	8	det	_
8	equivalent	equivalent	NN	_	5	dobj	5:A1=PPT;17:A1=PPT
9	of	of	IN	_	8	prep	_
10	55	0	CD	_	11	num	_
11	pounds	pound	NNS	_	9	pobj	_
12	for	for	IN	_	8	prep	_
13	each	each	DT	_	15	det	_
14	AstraZeneca	astrazeneca	NNP	_	15	nn	_
15	share	share	NN	p2=VBP	12	pobj	_
16	,	,	,	_	8	punct	_
17	split	split	VBN	p2=VBD|pb=split.01	8	partmod	_
18	between	between	IN	_	17	prep	17:A2=PPT
19	1.747	0	CD	_	20	num	_
20	shares	share	NNS	_	18	pobj	_
21	of	of	IN	_	20	prep	_
22	the	the	DT	_	24	det	_
23	new	new	JJ	_	24	amod	_
24	company	company	NN	_	21	pobj	_
25	and	and	CC	_	20	cc	_
26	2.476	0	CD	_	27	num	_
27	pence	penny	NNS	p2=NN	20	conj	_
28	in	in	IN	_	27	prep	_
29	cash	cash	NN	_	28	pobj	_
30	.	.	.	_	5	punct	_

1	Pfizer	pfizer	NNP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	in	in	IN	_	2	prep	2:AM-LOC
4	a	a	DT	_	5	det	_
5	statement	statement	NN	_	3	pobj	_
6	that	that	IN	_	10	complm	_
7	it	it	PRP	_	10	nsubj	10:A0=PAG;22:A0=PAG
8	wo	wo	MD	_	10	aux	10:AM-MOD
9	n't	not	RB	_	10	neg	10:AM-NEG
10	make	make	VB	pb=make.05	2	ccomp	2:A1=PPT
11	a	a	DT	_	13	det	_
12	hostile	hostile	JJ	_	13	amod	_
13	offer	offer	NN	_	10	dobj	10:AM-PRR
14	directly	directly	RB	_	10	advmod	10:AM-MNR
15	to	to	IN	_	10	prep	10:A2=DIR
16	AstraZeneca	astrazeneca	NNP	_	18	poss	_
17	's	's	POS	_	16	possessive	_
18	stockholders	stockholder	NNS	_	15	pobj	_
19	and	and	CC	_	10	cc	_
20	will	will	MD	_	22	aux	22:AM-MOD
21	only	only	RB	_	22	advmod	22:AM-ADV
22	proceed	proceed	VB	pb=proceed.01	10	conj	_
23	if	if	IN	_	28	mark	_
24	the	the	DT	_	25	det	_
25	company	company	NN	_	27	poss	_
26	's	's	POS	_	25	possessive	_
27	board	board	NN	_	28	nsubj	28:A0=PAG;29:A0=PAG
28	recommends	recommend	VBZ	pb=recommend.01	22	advcl	22:A1=PPT
29	accepting	accept	VBG	pb=accept.01	28	xcomp	28:A1=PPT
30	the	the	DT	_	31	det	_
31	deal	deal	NN	_	29	dobj	29:A1=PPT
32	.	.	.	_	2	punct	_

1	It	it	PRP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	the	the	DT	_	4	det	_
4	offer	offer	NN	_	5	nsubj	5:A0=PAG
5	represents	represent	VBZ	pb=represent.01	2	ccomp	2:A1=PPT
6	a	a	DT	_	9	det	_
7	45	0	CD	_	8	num	_
8	percent	percent	NN	_	9	nn	_
9	premium	premium	NN	p2=JJ	5	dobj	5:A1=PPT
10	to	to	IN	p2=TO	5	prep	_
11	AstraZeneca	astrazeneca	NNP	_	14	poss	_
12	's	's	POS	_	11	possessive	_
13	share	share	NN	_	14	nn	_
14	price	price	NN	_	10	pobj	_
15	of	of	IN	_	14	prep	_
16	37.82	0	CD	_	17	num	_
17	pounds	pound	NNS	_	15	pobj	_
18	on	on	IN	_	14	prep	_
19	April	april	NNP	_	18	pobj	_
20	17	0	CD	_	19	num	_
21	,	,	,	_	5	punct	_
22	before	before	IN	_	27	mark	_
23	rumors	rumor	NNS	_	27	nsubj	27:A1=PPT;28:A1=PPT
24	of	of	IN	_	23	prep	_
25	the	the	DT	_	26	det	_
26	deal	deal	NN	_	24	pobj	_
27	began	begin	VBD	pb=begin.01	5	advcl	_
28	circulating	circulate	VBG	pb=circulate.01	27	xcomp	27:C-A1
29	.	.	.	_	2	punct	_

1	Pfizer	pfizer	NNP	p2=NN	4	nn	_
2	CEO	ceo	NNP	p2=NN	4	nn	_
3	Ian	ian	NNP	_	4	nn	_
4	Read	read	NNP	_	5	nsubj	5:A0
5	said	say	VBD	pb=say.01	0	root	_
6	in	in	IN	_	5	prep	5:AM-LOC
7	a	a	DT	_	8	det	_
8	statement	statement	NN	_	6	pobj	_
9	that	that	IN	_	13	complm	_
10	the	the	DT	_	12	det	_
11	"	"	``	_	12	punct	_
12	combination	combination	NN	_	13	nsubj	13:A1=PPT
13	is	be	VBZ	pb=be.01	8	ccomp	5:A1=PPT
14	in	in	IN	p2=RB	13	prep	13:A2=PRD
15	the	the	DT	_	17	det	_
16	best	good	JJS	_	17	amod	_
17	interests	interest	NNS	_	14	pobj	_
18	of	of	IN	_	17	prep	_
19	all	all	DT	_	20	det	_
20	stakeholders	stakeholder	NNS	_	18	pobj	_
21	.	.	.	_	5	punct	_

1	We	we	PRP	_	2	nsubj	2:A1=PPT
2	are	be	VBP	pb=be.01	0	root	_
3	excited	excited	JJ	p2=VBN	2	acomp	2:A2=PRD
4	at	at	IN	_	3	prep	_
5	the	the	DT	_	6	det	_
6	opportunity	opportunity	NN	_	4	pobj	_
7	to	to	TO	_	8	aux	_
8	create	create	VB	pb=create.01	6	infmod	_
9	a	a	DT	_	11	det	_
10	scientific	scientific	JJ	_	11	amod	_
11	powerhouse	powerhouse	NN	_	8	dobj	8:A1=PPT
12	,	,	,	_	2	punct	_
13	delivering	deliver	VBG	pb=deliver.01	2	advcl	2:AM-ADV
14	great	great	JJ	_	15	amod	_
15	benefits	benefit	NNS	_	13	dobj	13:A1=PPT
16	to	to	IN	_	13	prep	13:A2=GOL
17	patients	patient	NNS	_	16	pobj	_
18	and	and	CC	_	17	cc	_
19	science	science	NN	_	17	conj	_
20	in	in	IN	_	17	prep	_
21	the	the	DT	_	22	det	_
22	UK	uk	NNP	_	20	pobj	_
23	and	and	CC	_	20	cc	_
24	across	across	IN	_	20	conj	_
25	the	the	DT	_	26	det	_
26	globe	globe	NN	_	24	pobj	_
27	.	.	.	_	2	punct	_
28	"	"	''	_	2	punct	_

1	Read	read	NNP	p2=VB	2	nsubj	2:A0=PAG
2	noted	note	VBD	pb=note.01	0	root	_
3	that	that	IN	_	15	complm	_
4	after	after	IN	_	15	prep	15:AM-TMP
5	speaking	speak	VBG	pb=speak.01	4	pcomp	_
6	with	with	IN	_	5	prep	5:AM-MNR
7	AstraZeneca	astrazeneca	NNP	_	8	nn	_
8	officials	official	NNS	_	6	pobj	_
9	earlier	early	RBR	p2=JJR	10	amod	_
10	Sunday	sunday	NNP	_	5	npadvmod	5:AM-TMP
11	,	,	,	_	15	punct	_
12	he	he	PRP	_	15	nsubj	15:A0
13	did	do	VBD	_	15	aux	_
14	n't	not	RB	_	15	neg	15:AM-NEG
15	think	think	VB	pb=think.01	2	ccomp	2:A1=PPT
16	its	its	PRP$	_	17	poss	_
17	board	board	NN	_	18	nsubj	22:A0=PAG;18:A1=PPT;20:A1=PPT
18	was	be	VBD	pb=be.01	15	ccomp	15:A1=PPT
19	"	"	``	_	20	punct	_
20	prepared	prepare	VBN	p2=VBD|pb=prepare.02	18	acomp	18:A2=PRD
21	to	to	TO	_	22	aux	_
22	recommend	recommend	VB	pb=recommend.01	20	xcomp	20:A2=PRP
23	a	a	DT	_	24	det	_
24	deal	deal	NN	_	22	dobj	22:A1=PPT
25	at	at	IN	_	22	prep	22:A3=PRD
26	a	a	DT	_	28	det	_
27	reasonable	reasonable	JJ	_	28	amod	_
28	price	price	NN	_	25	pobj	_
29	.	.	.	_	2	punct	_
30	"	"	''	_	2	punct	_

1	Pfizer	pfizer	NNP	_	2	nsubj	2:A0
2	said	say	VBD	pb=say.01	0	root	_
3	it	it	PRP	_	4	nsubj	4:A0
4	hopes	hope	VBZ	pb=hope.01	2	ccomp	2:A1=PPT
5	AstraZeneca	astrazeneca	NNP	_	7	poss	_
6	's	's	POS	_	5	possessive	_
7	shareholders	shareholder	NNS	_	9	nsubj	9:A0=PAG
8	will	will	MD	_	9	aux	9:AM-MOD
9	push	push	VB	pb=push.02	4	ccomp	4:A1=PPT
10	for	for	IN	_	9	prep	9:A2=PRD
11	the	the	DT	_	12	det	_
12	deal	deal	NN	_	10	pobj	_
13	.	.	.	_	2	punct	_

1	AstraZeneca	astrazeneca	NNP	_	4	nsubj	4:A0=PAG;9:A0=PAG
2	has	have	VBZ	_	4	aux	_
3	repeatedly	repeatedly	RB	_	4	advmod	4:AM-TMP
4	rejected	reject	VBN	pb=reject.01	0	root	_
5	Pfizer	pfizer	NNP	p2=NN	7	poss	_
6	's	's	POS	_	5	possessive	_
7	offers	offer	NNS	_	4	dobj	4:A1=PPT
8	,	,	,	_	4	punct	_
9	insisting	insist	VBG	pb=insist.01	4	advcl	4:AM-PRD
10	they	they	PRP	_	12	nsubj	12:A0=PAG
11	significantly	significantly	RB	_	12	advmod	12:AM-MNR
12	undervalue	undervalue	VBD	p2=VBP|pb=undervalue.01	9	ccomp	9:A1=PPT
13	the	the	DT	_	14	det	_
14	company	company	NN	_	12	dobj	12:A1=PPT
15	and	and	CC	_	14	cc	_
16	its	its	PRP$	_	17	poss	_
17	portfolio	portfolio	NN	_	14	conj	_
18	of	of	IN	_	14	prep	_
19	experimental	experimental	JJ	_	20	amod	_
20	drugs	drug	NNS	_	18	pobj	_
21	.	.	.	_	4	punct	_

1	The	the	DT	_	2	det	_
2	company	company	NN	_	9	nsubj	9:A0=PAG
3	and	and	CC	_	2	cc	_
4	British	british	JJ	_	6	amod	_
5	government	government	NN	_	6	nn	_
6	officials	official	NNS	_	2	conj	_
7	also	also	RB	_	9	advmod	9:AM-DIS
8	have	have	VBP	_	9	aux	_
9	raised	raise	VBN	pb=raise.01	0	root	_
10	concerns	concern	NNS	_	9	dobj	9:A1=PPT
11	about	about	IN	_	10	prep	_
12	the	the	DT	_	13	det	_
13	prospect	prospect	NN	_	11	pobj	_
14	of	of	IN	_	13	prep	_
15	job	job	NN	_	16	nn	_
16	cuts	cut	NNS	_	14	pobj	_
17	,	,	,	_	16	punct	_
18	facility	facility	NN	_	19	nn	_
19	closures	closure	NNS	_	16	conj	_
20	and	and	CC	_	19	cc	_
21	losing	lose	VBG	pb=lose.02	19	conj	_
22	some	some	DT	_	21	dobj	21:A1=PPT
23	of	of	IN	_	22	prep	_
24	the	the	DT	_	26	det	_
25	science	science	NN	_	26	nn	_
26	leadership	leadership	NN	_	23	pobj	_
27	in	in	IN	_	26	prep	_
28	the	the	DT	_	29	det	_
29	UK	uk	NNP	_	27	pobj	36:AM-LOC
30	,	,	,	_	29	punct	_
31	where	where	WRB	_	36	advmod	36:R-AM-LOC
32	London	london	NNP	_	34	hmod	_
33	-	-	HYPH	_	34	hyph	_
34	based	base	VBN	_	35	amod	_
35	AstraZeneca	astrazeneca	NNP	_	36	nsubj	36:A1=PPT
36	is	be	VBZ	pb=be.01	29	rcmod	_
37	the	the	DT	_	41	det	_
38	second	#ord#	RB	_	40	hmod	_
39	-	-	HYPH	_	40	hyph	_
40	biggest	big	JJS	p2=RBS	41	amod	_
41	drugmaker	drugmaker	NN	_	36	attr	36:A2=PRD
42	,	,	,	_	41	punct	_
43	behind	behind	IN	p2=RB	36	prep	_
44	GlaxoSmithKline	glaxosmithkline	NNP	_	45	nn	_
45	PLC	plc	NNP	_	43	pobj	_
46	.	.	.	_	9	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	nsubj	3:A0=PAG
2	has	have	VBZ	_	3	aux	_
3	made	make	VBN	pb=make.02	0	root	_
4	assurances	assurance	NNS	_	6	nn	_
5	such	such	JJ	_	6	amod	_
6	cuts	cut	NNS	_	8	nsubj	8:A1=PPT
7	would	would	MD	_	8	aux	8:AM-MOD
8	be	be	VB	pb=be.01	3	ccomp	3:A1=PRD
9	limited	limited	JJ	p2=VBN	8	acomp	8:A2=PRD
10	.	.	.	_	3	punct	_

1	It	it	PRP	_	3	nsubjpass	5:A0=PAG
2	's	's	VBZ	_	3	auxpass	_
3	promised	promise	VBN	pb=promise.01	0	root	_
4	to	to	TO	_	5	aux	_
5	complete	complete	VB	p2=JJ|pb=complete.01	3	xcomp	3:A2=PPT
6	AstraZeneca	astrazeneca	NNP	_	11	poss	_
7	's	's	POS	_	6	possessive	_
8	research	research	NN	_	11	nn	_
9	and	and	CC	_	8	cc	_
10	development	development	NN	_	8	conj	_
11	hub	hub	NN	_	5	dobj	5:A1=PPT
12	in	in	IN	_	11	prep	_
13	Cambridge	cambridge	NNP	_	12	pobj	_
14	.	.	.	_	3	punct	_

1	And	and	CC	_	3	cc	3:AM-DIS
2	it	it	PRP	_	3	nsubj	3:A0=PAG;5:A0
3	pledged	pledge	VBD	pb=pledge.01	0	root	_
4	to	to	TO	_	5	aux	_
5	establish	establish	VB	pb=establish.01	3	xcomp	3:A2=PPT
6	the	the	DT	_	8	det	_
7	new	new	JJ	_	8	amod	_
8	company	company	NN	_	11	poss	_
9	's	's	POS	_	8	possessive	_
10	tax	tax	NN	_	11	nn	_
11	residence	residence	NN	_	5	dobj	5:A1=PPT
12	,	,	,	_	5	punct	_
13	but	but	CC	_	10	cc	_
14	not	not	RB	_	15	neg	_
15	headquarters	headquarter	NNS	p2=NN	5	conj	23:A0
16	,	,	,	_	15	punct	_
17	in	in	IN	_	15	prep	_
18	England	england	NNP	_	17	pobj	_
19	,	,	,	_	15	punct	_
20	which	which	WDT	_	23	nsubj	23:R-A0
21	would	would	MD	_	23	aux	23:AM-MOD
22	significantly	significantly	RB	_	23	advmod	23:A2=EXT
23	reduce	reduce	VB	pb=reduce.01	15	rcmod	_
24	its	its	PRP$	_	27	poss	_
25	future	future	JJ	p2=NN	27	amod	_
26	tax	tax	NN	_	27	nn	_
27	rate	rate	NN	_	23	dobj	23:A1=PPT
28	.	.	.	_	3	punct	_

1	But	but	CC	_	3	cc	3:AM-DIS
2	layoffs	layoff	NNS	_	3	nsubj	3:A1=PPT
3	are	be	VBP	pb=be.01	0	root	_
4	inevitable	inevitable	JJ	_	3	acomp	3:A2=PRD
5	in	in	IN	_	3	prep	3:AM-LOC
6	big	big	JJ	_	7	amod	_
7	mergers	merger	NNS	_	5	pobj	_
8	,	,	,	_	3	punct	_
9	and	and	CC	_	3	cc	_
10	Pfizer	pfizer	NNP	_	11	nsubj	11:A0=PAG;16:A0=PAG
11	has	have	VBZ	pb=have.03	3	conj	_
12	a	a	DT	_	14	det	_
13	track	track	NN	_	14	nn	_
14	record	record	NN	_	11	dobj	11:A1=PPT
15	of	of	IN	_	14	prep	_
16	eliminating	eliminate	VBG	pb=eliminate.01	15	pcomp	_
17	tens	#crd#	NNS	_	16	dobj	16:A1=PPT
18	of	of	IN	_	17	prep	_
19	thousands	#crd#	NNS	_	18	pobj	_
20	of	of	IN	_	19	prep	_
21	jobs	job	NNS	_	20	pobj	_
22	around	around	IN	_	21	prep	_
23	the	the	DT	_	24	det	_
24	world	world	NN	_	22	pobj	_
25	as	as	IN	_	16	prep	16:AM-CAU
26	a	a	DT	_	27	det	_
27	result	result	NN	_	25	pobj	_
28	of	of	IN	_	27	prep	_
29	megadeals	megadeal	NNS	_	28	pobj	_
30	.	.	.	_	11	punct	_

1	While	while	IN	_	5	mark	_
2	Pfizer	pfizer	NNP	_	5	nsubjpass	_
3	is	be	VBZ	_	5	auxpass	_
4	best	well	RBS	p2=RB	5	advmod	_
5	known	known	JJ	p2=VBN	27	advcl	27:AM-ADV
6	to	to	IN	_	5	prep	_
7	the	the	DT	_	8	det	_
8	public	public	NN	p2=JJ	6	pobj	_
9	for	for	IN	_	5	prep	_
10	Viagra	viagra	NNP	p2=NN	9	pobj	_
11	,	,	,	_	10	punct	_
12	cholesterol	cholesterol	NN	_	13	nn	_
13	fighter	fighter	NN	_	14	nn	_
14	Lipitor	lipitor	NNP	p2=NN	37	nn	_
15	and	and	CC	_	14	cc	_
16	other	other	JJ	_	19	amod	_
17	widely	widely	RB	_	18	advmod	18:AM-EXT
18	used	use	VBN	p2=JJ|pb=use.01	19	amod	_
19	medicines	medicine	NNS	_	14	conj	18:A1=PPT
20	,	,	,	_	19	punct	_
21	in	in	IN	_	27	prep	27:AM-LOC
22	the	the	DT	_	24	det	_
23	pharmaceutical	pharmaceutical	JJ	p2=NN	24	amod	_
24	industry	industry	NN	_	21	pobj	_
25	it	it	PRP	_	27	nsubjpass	27:A1=PPT
26	's	's	VBZ	_	27	auxpass	_
27	known	know	VBN	p2=JJ|pb=know.01	0	root	_
28	for	for	IN	_	27	prep	27:A2=PRD
29	two	#crd#	CD	_	31	num	_
30	other	other	JJ	_	31	amod	_
31	things	thing	NNS	_	28	pobj	43:A0
32	:	:	:	_	31	punct	_
33	marketing	marketing	NN	p2=VBG	34	nn	_
34	muscle	muscle	NN	_	31	appos	_
35	and	and	CC	_	34	cc	_
36	mega	mega	JJ	p2=NN	37	amod	_
37	mergers	merger	NNS	_	34	conj	_
38	,	,	,	_	37	punct	_
39	which	which	WDT	_	43	nsubj	43:R-A0
40	together	together	RB	_	43	advmod	43:AM-MNR
41	have	have	VBP	_	43	aux	_
42	repeatedly	repeatedly	RB	_	43	advmod	43:AM-MNR
43	propelled	propel	VBN	pb=propel.01	31	rcmod	_
44	it	it	PRP	_	43	dobj	43:A1=PPT
45	to	to	IN	_	43	prep	43:A2=GOL
46	the	the	DT	_	47	det	_
47	top	top	NN	_	45	pobj	_
48	.	.	.	_	27	punct	_

1	Copyright	copyright	NN	_	0	root	_
2	2014	0	CD	_	1	num	_
3	©	©	NNP	p2=,	5	nn	_
4	U.S.	u.s.	NNP	_	5	nn	_
5	News	news	NNP	_	1	appos	_
6	&	&	CC	_	5	cc	_
7	World	world	NNP	_	9	nn	_
8	Report	report	NNP	_	9	nn	_
9	LP	lp	NNP	_	5	conj	_
10	.	.	.	_	1	punct	_

